Medscape Educ.: Reducing Residual Risk for Cardiovascular Disease Omega-3 Fatty Acids in Cardiology | AMRN Message Board Posts

Amarin Corporation plc

  AMRN website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

AMRN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4761 of 7342  at  8/22/2019 9:47:51 PM  by

cmm3rd


Medscape Educ.: Reducing Residual Risk for Cardiovascular Disease Omega-3 Fatty Acids in Cardiology Practice

CME event for healthcare professionals who manage dyslipidemia.
 
 
Activity Overview
 

The correlation between elevations in total cholesterol or low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) risk is well known by healthcare professionals. However, knowledge and experience of lipid abnormalities outside of LDL-C, such as pathologic levels of triglycerides, is very limited, despite epidemiologic data that support the contribution of hypertriglyceridemia to the development and progression of atherosclerotic disease.

Recent data has shown that pure eicosapentaenoic acid ethyl ester (EPA) can reduce the risk for CV events. However, healthcare practitioners (HCPs) in cardiology, primary care, diabetology/endocrinology, and other settings have limited knowledge about the biologic and antiatherosclerotic properties of EPA and the potential for its combined use with statins to reduce residual CV risk in patients with mixed dyslipidemia at high risk for CV events.

Join Drs Deepak Bhatt, Preston Mason, and William Weintraub as they walk us through the current omega-3 landscape and how they can improve CV outcomes in patients with dyslipidemia.

 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 213
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...